FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092194966> ?p ?o ?g. }

• W3092194966 endingPage "1073" @default.
• W3092194966 startingPage "1071" @default.
• W3092194966 abstract "The long-term effects of surviving COVID-19 have become a new focus of attention for clinicians and researchers. This focus has been driven partly by concerns about late ill-effects of a previously unknown virus, but recognised generic patterns of chronic disease after critical illness also exist. These patterns are termed PICS, an acronym both for post-intensive care syndrome and for persistent inflammation, immunosuppression, and catabolism syndrome. We recommend unifying post-COVID-19 research aims with those of PICS research and propose a novel approach to its management by repurposing drugs that are approved, inexpensive, and safe. Severe COVID-19 pneumonia causes acute respiratory distress syndrome (ARDS). Intensive care unit (ICU) stays of patients with ARDS are lengthy and characterised by severe hypoxaemia, extrapulmonary organ failures, and a marked inflammatory response. Follow-up data from young (<30 years) populations with a range of critical illnesses and no comorbidities, and studies assessing dose–responses (dose of illness vs response of morbidity) of organ dysfunction and tissue injury, suggest that an adverse long-term reprogramming of multiple organ systems can occur during such critical illness.1Stewart IJ Sosnov JA Howard JT et al.Retrospective analysis of long-term outcomes after combat injury: a hidden cost of war.Circulation. 2015; 132: 2126-2133Crossref PubMed Scopus (65) Google Scholar People who survive lose weight and are debilitated, often with cognitive impairments. A hysteresis of body-mass recovery in different tissue compartments occurs and metabolic control is often disrupted, with the development of type 2 diabetes and adipose gain commonly reported in affected individuals. Organs undergo microscopic damage at the time of acute inflammation and display imperfect repair, with acute kidney injury and cardiovascular dysfunction transitioning to chronic kidney disease and post-ICU major adverse cardiac events.1Stewart IJ Sosnov JA Howard JT et al.Retrospective analysis of long-term outcomes after combat injury: a hidden cost of war.Circulation. 2015; 132: 2126-2133Crossref PubMed Scopus (65) Google Scholar These processes occur in the context of low-grade inflammation and functional immunosuppression, which predisposes individuals who survive admission to ICU, and particularly those with PICS, to secondary infections.2Yende S Kellum JA Talisa VB et al.Long-term host immune response trajectories among hospitalized patients with sepsis.JAMA Netw Open. 2019; 2e198686Crossref PubMed Scopus (73) Google Scholar Although physical activity counters the proinflammatory effects of sedentarism, enhanced recovery programmes against a backdrop of residual inflammation have not translated to benefit, suggesting a potential role for pharmacological intervention.3Griffith DM Lewis S Rossi AG et al.Systemic inflammation after critical illness: relationship with physical recovery and exploration of potential mechanisms.Thorax. 2016; 71: 820-829Crossref PubMed Scopus (45) Google Scholar If prolonged critical illness, including that associated with COVID-19, causes patients to develop chronic inflammation, thrombosis, and fibrosis, antagonists of these processes might be beneficial for survivors. The CANTOS trial showed that major adverse cardiac events, lung cancer, and anaemia rates were reduced in groups with evidence of low-grade inflammation when treated for secondary prevention with the interleukin-1β (IL-1β) monoclonal antibody canakinumab.4Ridker PM Everett BM Thuren T et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med. 2017; 377: 1119-1131Crossref PubMed Scopus (5326) Google Scholar However, our opinion is that the critical care specialty is not yet in a position to conduct large-scale trials of such powerful anti-inflammatory drugs in ICU survivors. The CANTOS and COLCOT trials showed that reducing IL-1β-related inflammation increases infection risk, an important consideration in the functionally immunosuppressed PICS population.2Yende S Kellum JA Talisa VB et al.Long-term host immune response trajectories among hospitalized patients with sepsis.JAMA Netw Open. 2019; 2e198686Crossref PubMed Scopus (73) Google Scholar However, other established cardiometabolic therapeutics with good clinical rationale and excellent safety profiles already exist and hold great promise for ICU survivors. These drugs are in a prime position to be trialled immediately in large numbers of patients with COVID-19-associated PICS, and such studies might provide a better understanding of who, if anyone, might benefit from IL-1β targeting. Non-randomised studies suggest that renin–angiotensin–aldosterone system (RAAS) inhibitors reduce mortality after discharge from the ICU in people who had critical illness with acute kidney injury, whereas preclinical studies suggest a potentially beneficial modulation of frailty in models of age-associated frailty.5Gayat E Hollinger A Cariou A et al.Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.Intensive Care Med. 2018; 44: 598-605Crossref PubMed Scopus (63) Google Scholar The SSCILL trial aims to test whether a RAAS modulator with suspected anti-inflammatory and known antifibrotic effects could be used in this group of patients with PICS to reduce major adverse cardiac events.6Intensive Care SocietyResearch prioritisation exercise SOA 2019: session 23.https://icspodcast.libsyn.com/research-prioritisation-exercise-soa-2019-session-23Date: 2019Date accessed: October 5, 2020Google Scholar However, other drugs, including RAAS modulators, should also be trialled while data for PICS biology accumulates. Statin trials in healthy patients with elevated high-sensitivity C-reactive protein (CRP) and older patients (>75 years) without atherosclerosis show how reductions in cardiovascular risk, high-sensitivity CRP, and rates of pneumonia and deep vein thrombosis can be achieved with low-risk drugs that, among other things, increase concentrations of proresolution mediators (eg, resolvins).7Dalli J Chiang N Serhan CN Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections.Nat Med. 2015; 21: 1071-1075Crossref PubMed Scopus (193) Google Scholar Other drugs, or dietary supplementation with compounds that increase proresolution mediators and reduce thrombo-inflammation, might also be expected to reduce cardiovascular and overall morbidity in patients with PICS; cardiovascular trials of aspirin and icosapent ethyl provide evidence of efficacy. In the MANAGE trial,8Devereaux PJ Duceppe E Guyatt G et al.Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.Lancet. 2018; 391: 2325-2334Summary Full Text Full Text PDF PubMed Scopus (196) Google Scholar a population having non-cardiac surgery, which overlaps and shares similarities with the PICS population through the presence of non-ischaemic myocardial injuries, was found to have reduced cardiovascular morbidity at follow-up when treated with the antithrombotic dabigatran; further trials of dabigatran in patients with PICS are warranted. Modulators of metabolism could also counteract numerous problems reported in patients with PICS. Multiple phase 3 studies of SGLT2 inhibitors repeatedly show improvements in metabolic and fibrotic cardiorenal outcomes even in the absence of diabetes. Metformin could similarly improve cardiometabolic profiles while also modulating the immunoparesis noted during and after critical illnesses.9Cheng SC Scicluna BP Arts RJ et al.Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis.Nat Immunol. 2016; 17: 406-413Crossref PubMed Scopus (373) Google Scholar Systemic metabolism, energy balance, and immunity are neurally mediated through the sympathetic nervous system. β-Adrenoceptor blockers are anti-arrhythmics with proven benefit in the cardiovascular arena, but might also benefit patients with PICS by reducing systemic metabolic rate and catabolism, decreasing bone marrow replicative stress, and modulating immune dysfunction.10Mohammadpour H MacDonald CR Qiao G et al.β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells.J Clin Invest. 2019; 129: 5537-5552Crossref PubMed Scopus (119) Google Scholar Nutritional supplements, such as niacin and folic acid, should also be trialled in PICS, because beneficial effects on muscle and the cardiovascular system, mediated through effects on DNA methylation and cellular energetics, are potentially attainable at low risk.11Pirinen E Auranen M Khan NA et al.Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy.Cell Metab. 2020; 31 (90.e5): 1078Summary Full Text Full Text PDF PubMed Scopus (104) Google Scholar Through large international, collaborative research projects, the ICU community has the opportunity to reduce readmission to hospital and the ICU while improving overall quality of life, healthspan, societal productivity, and the lifespan for people who have been in ICU (panel). The James Lind Alliance research prioritisation exercise in intensive care shows that patients would welcome trials in this area. Therefore, we propose that the ICU community should organise large, international, pragmatic, multicentre platform trials for ICU survivors, in a manner analogous to the RECOVERY trial, to potentially decipher whether or not these drugs can be efficacious for those who have survived critical illnesses such as COVID-19. We suggest that the research pathway for such trials should be based on prognostic enrichment through clinical and cardiovascular or immune biomarker profiles, and initially use established drugs that modify cardiometabolic risk in ICU survivors who might not have traditionally recognised cardiovascular risk factors, through randomised controlled trials led by intensive care specialists. We are already on the path to starting this process with SSCILL in sepsis, polytrauma, and ARDS, and we encourage others to join us.PanelConsiderations for researchPost-intensive care syndrome (PICS) often occurs after prolonged critical illnesses, such as COVID-19-associated acute respiratory distress syndrome, and involves persistent inflammation, immunosuppression, and catabolism.Substantial cardiovascular morbidity and mortality accompany PICS, even in young, fit populations without traditional cardiovascular risk factors.The harms of potent anti-inflammatory drugs that are used to counter chronic cardiovascular disease and fibrosis are unquantified in PICS; further data could show whether these therapies offer some benefit.Low-risk cardiometabolic and antithrombotic drugs might be beneficial and large international, multicentre trials are needed to formally test their efficacy.Avoiding polypharmacy while prognostically enriching the trial population (and so increasing the study's signal to noise ratio) could be done through the use of clinical characteristics or cardiovascular and immune biomarkers to select patients more appropriate for specific trials.Study designs should involve optimising discharge therapy before patients start any new trial drug and account for the fact that many survivors of critical illness already take one or more of the drugs of interest.Involving individuals with PICS to help guide research priorities is crucially important to ensure that research remains patient-centred. Post-intensive care syndrome (PICS) often occurs after prolonged critical illnesses, such as COVID-19-associated acute respiratory distress syndrome, and involves persistent inflammation, immunosuppression, and catabolism. Substantial cardiovascular morbidity and mortality accompany PICS, even in young, fit populations without traditional cardiovascular risk factors. The harms of potent anti-inflammatory drugs that are used to counter chronic cardiovascular disease and fibrosis are unquantified in PICS; further data could show whether these therapies offer some benefit. Low-risk cardiometabolic and antithrombotic drugs might be beneficial and large international, multicentre trials are needed to formally test their efficacy. Avoiding polypharmacy while prognostically enriching the trial population (and so increasing the study's signal to noise ratio) could be done through the use of clinical characteristics or cardiovascular and immune biomarkers to select patients more appropriate for specific trials. Study designs should involve optimising discharge therapy before patients start any new trial drug and account for the fact that many survivors of critical illness already take one or more of the drugs of interest. Involving individuals with PICS to help guide research priorities is crucially important to ensure that research remains patient-centred. For more on James Lind Alliance priority setting in intensive care see https://www.jla.nihr.ac.uk/priority-setting-partnerships/intensive-careFor more on the RECOVERY trial see https://www.recoverytrial.net For more on James Lind Alliance priority setting in intensive care see https://www.jla.nihr.ac.uk/priority-setting-partnerships/intensive-care For more on the RECOVERY trial see https://www.recoverytrial.net MNB has received research awards from the UK Intensive Care Society for the pilot randomised controlled trial SSCILL. All other authors declare no competing interests." @default.
• W3092194966 created "2020-10-15" @default.
• W3092194966 creator A5002138132 @default.
• W3092194966 creator A5004667593 @default.
• W3092194966 creator A5033858774 @default.
• W3092194966 creator A5043836434 @default.
• W3092194966 creator A5052321624 @default.
• W3092194966 creator A5073546238 @default.
• W3092194966 date "2020-11-01" @default.
• W3092194966 modified "2023-10-11" @default.
• W3092194966 title "COVID-19 recovery: potential treatments for post-intensive care syndrome" @default.
• W3092194966 cites W2235275437 @default.
• W3092194966 cites W2296531152 @default.
• W3092194966 cites W2344294128 @default.
• W3092194966 cites W2748400555 @default.
• W3092194966 cites W2803977650 @default.
• W3092194966 cites W2806134060 @default.
• W3092194966 cites W2965665569 @default.
• W3092194966 cites W2978526767 @default.
• W3092194966 cites W3022810443 @default.
• W3092194966 cites W4241413696 @default.
• W3092194966 doi "https://doi.org/10.1016/s2213-2600(20)30457-4" @default.
• W3092194966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7550044" @default.
• W3092194966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33058770" @default.
• W3092194966 hasPublicationYear "2020" @default.
• W3092194966 type Work @default.
• W3092194966 sameAs 3092194966 @default.
• W3092194966 citedByCount "20" @default.
• W3092194966 countsByYear W30921949662021 @default.
• W3092194966 countsByYear W30921949662022 @default.
• W3092194966 countsByYear W30921949662023 @default.
• W3092194966 crossrefType "journal-article" @default.
• W3092194966 hasAuthorship W3092194966A5002138132 @default.
• W3092194966 hasAuthorship W3092194966A5004667593 @default.
• W3092194966 hasAuthorship W3092194966A5033858774 @default.
• W3092194966 hasAuthorship W3092194966A5043836434 @default.
• W3092194966 hasAuthorship W3092194966A5052321624 @default.
• W3092194966 hasAuthorship W3092194966A5073546238 @default.
• W3092194966 hasBestOaLocation W30921949661 @default.
• W3092194966 hasConcept C116675565 @default.
• W3092194966 hasConcept C126322002 @default.
• W3092194966 hasConcept C159047783 @default.
• W3092194966 hasConcept C17744445 @default.
• W3092194966 hasConcept C177713679 @default.
• W3092194966 hasConcept C199539241 @default.
• W3092194966 hasConcept C2778137277 @default.
• W3092194966 hasConcept C2779134260 @default.
• W3092194966 hasConcept C2779473830 @default.
• W3092194966 hasConcept C2909376813 @default.
• W3092194966 hasConcept C3006700255 @default.
• W3092194966 hasConcept C3007834351 @default.
• W3092194966 hasConcept C3008058167 @default.
• W3092194966 hasConcept C524204448 @default.
• W3092194966 hasConcept C71924100 @default.
• W3092194966 hasConcept C89623803 @default.
• W3092194966 hasConceptScore W3092194966C116675565 @default.
• W3092194966 hasConceptScore W3092194966C126322002 @default.
• W3092194966 hasConceptScore W3092194966C159047783 @default.
• W3092194966 hasConceptScore W3092194966C17744445 @default.
• W3092194966 hasConceptScore W3092194966C177713679 @default.
• W3092194966 hasConceptScore W3092194966C199539241 @default.
• W3092194966 hasConceptScore W3092194966C2778137277 @default.
• W3092194966 hasConceptScore W3092194966C2779134260 @default.
• W3092194966 hasConceptScore W3092194966C2779473830 @default.
• W3092194966 hasConceptScore W3092194966C2909376813 @default.
• W3092194966 hasConceptScore W3092194966C3006700255 @default.
• W3092194966 hasConceptScore W3092194966C3007834351 @default.
• W3092194966 hasConceptScore W3092194966C3008058167 @default.
• W3092194966 hasConceptScore W3092194966C524204448 @default.
• W3092194966 hasConceptScore W3092194966C71924100 @default.
• W3092194966 hasConceptScore W3092194966C89623803 @default.
• W3092194966 hasIssue "11" @default.
• W3092194966 hasLocation W30921949661 @default.
• W3092194966 hasLocation W30921949662 @default.
• W3092194966 hasLocation W30921949663 @default.
• W3092194966 hasOpenAccess W3092194966 @default.
• W3092194966 hasPrimaryLocation W30921949661 @default.
• W3092194966 hasRelatedWork W3003901880 @default.
• W3092194966 hasRelatedWork W3004826915 @default.
• W3092194966 hasRelatedWork W3005417802 @default.
• W3092194966 hasRelatedWork W3007868867 @default.
• W3092194966 hasRelatedWork W3009669391 @default.
• W3092194966 hasRelatedWork W3020699490 @default.
• W3092194966 hasRelatedWork W3031607536 @default.
• W3092194966 hasRelatedWork W3087206508 @default.
• W3092194966 hasRelatedWork W4206419631 @default.
• W3092194966 hasRelatedWork W3127156785 @default.
• W3092194966 hasVolume "8" @default.
• W3092194966 isParatext "false" @default.
• W3092194966 isRetracted "false" @default.
• W3092194966 magId "3092194966" @default.
• W3092194966 workType "article" @default.